Charles River Laboratories to Present at Jefferies Global Healthcare Conference November 16th, 2026|Business Wire| WILMINGTON, Mass.–(BUSINESS WIRE)–Charles River Laboratories to Present at Jefferies Global Healthcare Conference Please leave this field empty Subscribe to Our Newsletter We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information. Please check your Inbox or Spam folder now to confirm your subscription. Like this post? Share it! FacebookXLinkedInEmail Related Posts Guardian Pharmacy Services, Inc. to Participate in Upcoming Citi Annual Global Healthcare Conference November 16th, 2026 | 0 Comments Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa November 16th, 2026 | 0 Comments Vega Health Named to CB Insights’ 2026 Digital Health 50 November 16th, 2026 | 0 Comments ENDRA Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update November 16th, 2026 | 0 Comments Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities November 16th, 2026 | 0 Comments FDA Approves Genentech’s WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer November 16th, 2026 | 0 Comments Cognito’s Non-Invasive, At-Home Therapy, Spectris®, Showed Consistent Slowing of Cognitive and Functional Decline in Early Symptomatic Alzheimer’s Disease in HOPE Pivotal Study November 16th, 2026 | 0 Comments Fuze Health Advances Chronic Care Through Its Technology-Led Intelligent Care Platform and Partner Collaboration November 16th, 2026 | 0 Comments U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as the First Companion Diagnostic in the U.S. for WILSERDLY (giredestrant) in Combination with Everolimus for ER-Positive, HER2-Negative, ESR1-Mutated Advanced Breast Cancer November 16th, 2026 | 0 Comments Instem Unveils Unified, AI-Enabled Platform to Transform Preclinical R&D November 16th, 2026 | 0 Comments OMNIVISION and Myriad Fiber Imaging Jointly Introduce New Integrated Surgical Visualization Platform for Endoscopic and Robotic Applications November 16th, 2026 | 0 Comments Every Cure and OpenEvidence Partner to Repurpose Drugs Where Commercial Incentives Fall Short November 16th, 2026 | 0 Comments